The antibody drug conjugate (ADC) development company, Glythera, has been granted exclusive, worldwide rights to Cancer Research UK’s novel CDK11 inhibitor programme for the development of multiple ADCs. Under the
Tag "Cancer Research UK"
Advertisements
